B.Riley initiates coverage on Microbot Medical stock with Buy rating

Investment firm B. Riley Securities initiated formal analyst coverage on Microbot Medical Inc. on May 22, 2024, issuing a 'Buy' rating and a $7.00 price target for the company's stock trading on the Nasdaq. The move comes as Wall Street analysts increasingly focus on the promising trajectory of Microbot's surgical robotics technology, specifically its flagship Liberty Endovascular Robotic System. B. Riley’s positive assessment is rooted in the device's potential to revolutionize minimally invasive procedures and the company's clear path toward clinical validation and commercialization in the United States and international markets. Microbot Medical, a clinical-stage medical device company, is currently navigating the regulatory landscape with its Liberty system, which aims to be the world's first fully disposable robotic system for endovascular procedures. By eliminating the need for large, capital-intensive equipment and specialized infrastructure, the Liberty system is designed to reduce radiation exposure for physicians and improve the precision of catheter-based interventions. The $7.00 price target set by B. Riley suggests a significant upside potential from the stock's current trading levels, reflecting confidence in the company's upcoming IDE (Investigational Device Exemption) clinical trial results. The initiation of coverage by a prominent firm like B. Riley serves as a critical milestone for Microbot, as it often leads to increased visibility among institutional investors and enhances market liquidity. Industry experts suggest that the surgical robotics sector is ripe for disruption, and Microbot's focus on portability and disposability addresses key pain points in modern operating rooms. As the company prepares for its multi-center human clinical trials, the financial community will be closely monitoring its ability to meet enrollment milestones and demonstrate the safety and efficacy of its robotic platform.